Takeaways from the NKF SCM26: Embracing the Evolution

The National Kidney Foundation (NKF) 2026 Spring Clinical Meetings (SCM26) in New Orleans this month confirmed that nephrology is at a pivotal inflection point. Across chronic kidney disease (CKD), immunoglobulin A (IgA) nephropathy (IgAN), apolipoprotein L1 (APOL1)–mediated kidney disease (AMKD) and focal segmental glomerulosclerosis (FSGS), the meeting highlighted growing momentum behind biomarker-guided treatment selection, genetic stratification, multidisciplinary care coordination, and real-world implementation strategies designed to improve patient outcomes across the kidney care continuum.

The future of care will depend not only on therapeutic innovation but also on operational execution—including patient identification, access to genetic testing, culturally responsive care, multidisciplinary coordination, and real-world usability within increasingly complex treatment paradigms. Central to this vision are earlier intervention, accelerated drug development, improved equity and access, and stronger integration of patient-centered care.

Precision Nephrology Comes of Age

SCM26 continues to emphasize translational and practical nephrology

The conference positioned itself as a forum for translating scientific advances into real-world clinical practice for multidisciplinary kidney teams. Pure mechanism-of-action education is no longer sufficient. Operational implementation and practical integration into care delivery are increasingly central.

Multidisciplinary kidney care is becoming strategically important

Advanced practice providers, pharmacists, nurses, social workers, genetic counselors, registered dieticians, and care coordinators are increasingly influential in therapy adoption, patient education, and long-term disease management.

Nephrology is becoming more optimistic

Historically, nephrology conferences have often reflected frustration over limited treatment options, slow therapeutic progress, and delayed diagnosis. In contrast, SCM26 conveyed a more optimistic tone—driven by expanding therapeutic pipelines, validated surrogate endpoints, accelerated approvals, advances in precision medicine, biomarker science, genetics, and AI-enabled disease modeling.

Rare glomerular disease momentum appears strong

The field is increasingly segmented into biologically defined disease subsets, with significant attention focused on IgAN, FSGS, and AMKD. Across these disease states, the meeting demonstrated growing confidence in targeted therapies, biomarker-guided treatment selection, genetic stratification, and layered treatment approaches designed to alter long-term disease trajectory rather than simply managing progression.

Speakers emphasized that FSGS should no longer be viewed as a singular disease entity but rather as a histologic pattern encompassing multiple underlying etiologies—including genetic, maladaptive, immune-mediated, and APOL1-associated forms. This continued shift away from purely histologic classification toward biology-driven disease characterization further reinforces the broader movement toward precision nephrology.

AMKD was discussed as a biologically distinct genetic podocytopathy with emerging targeted therapies, further reinforcing the growing role of genetic stratification and precision medicine approaches across nephrology.

IgA Nephropathy Transitions Toward Earlier Mechanism-Driven Care

From a “supportive care disease” to a precision immunology disease

Across multiple sessions, speakers repeatedly framed IgA nephropathy as immunologically driven, biologically heterogeneous, progressive, and increasingly warranting earlier targeted intervention, even at lower proteinuria thresholds.

The older paradigm centered on maximizing supportive care, such as renin-angiotensin-aldosterone system (RAAS) inhibition and observation, appears to be eroding. In its place, the field is increasingly embracing earlier biologically targeted intervention strategies alongside foundational kidney-protective therapies.

Discussions surrounding the gut-kidney axis further reinforced the growing emphasis on upstream immune dysregulation in IgA nephropathy pathogenesis. Speakers repeatedly framed mucosal immune activation, B‑cell activating factor (BAFF) and a proliferation‑inducing ligand (APRIL) signaling, and the four-hit hypothesis as increasingly well-established biologic frameworks underpinning earlier, more targeted treatment approaches.

Nephrologists are thinking beyond just proteinuria

Although proteinuria thresholds, rapid reduction kinetics, KDIGO targets, and surrogate endpoints remain central to disease monitoring and regulatory strategy, treatment is increasingly focused on disease modification, the preservation of kidney function, avoidance of dialysis and end-stage renal disease, and preservation of long-term quality of life.

BAFF/APRIL and Complement Biology Gain Momentum

Broad scientific legitimacy for BAFF/APRIL biology

Mechanism-based education was another defining theme across the conference. There was repeated emphasis on BAFF/APRIL signaling, the gut-kidney axis, podocyte biology, activation of the alternative pathway, and biomarker interpretation. The field increasingly expects biologically coherent storytelling, mechanism fluency, and disease-driving framing.

Multiple companies and independent speakers reinforced the four-hit hypothesis, upstream immune dysregulation, B-cell involvement, and the biologic relevance of BAFF/APRIL. Importantly, these concepts were discussed as established clinical logic rather than speculative science, suggesting that nephrologists are increasingly comfortable with immune-directed treatment paradigms in IgA nephropathy.

A notable shift emerging from the meeting is that the key question may no longer be whether BAFF/APRIL biology matters but rather which therapeutic approach ultimately proves most effective, durable, practical, and scalable in real-world care.

Combination Therapy and Real-World Practicality

Combination and layered treatments may shape future management

Across sessions, speakers repeatedly described future IgA nephropathy care as involving layered therapy approaches that may include RAAS inhibition, sodium-glucose cotransporter 2 inhibitors, endothelin receptor antagonists, complement inhibition, dual BAFF/APRIL modulation, and potentially steroids in select patients.

The future market may therefore not behave as predicted by a model of single-agent dominance. Instead, multiple mechanistic classes may coexist, with treatment sequencing, combination strategies, and patient selection becoming increasingly important.

Operational simplicity and workflow integration may become key differentiators

Future differentiation among therapies may increasingly depend not only on efficacy but also on convenience, safety, monitoring burden, route of administration, treatment durability, workflow integration, and overall practicality within nephrology care delivery.

As more targeted therapies enter the market, the balance between clinical efficacy and operational simplicity may become an increasingly important factor in shaping real-world adoption.

Health Equity and Care Infrastructure

A central theme of SCM26

Health equity was not treated as a peripheral topic at SCM26; rather, it was integrated throughout discussions surrounding CKD care, transplantation, patient education, culturally responsive care, and patient navigation programs.

Importantly, the nephrology community increasingly framed disparities as systems-level challenges rather than solely as failures of patient adherence. Discussions repeatedly emphasized the importance of culturally responsive education, access to nephrology care, community partnerships, patient navigation, access to genetic testing, and multidisciplinary coordination.

These themes may carry growing implications for pharmaceutical companies and health care systems alike, particularly as precision medicine approaches expand into historically underserved patient populations.

One notable example was the EMBARK Awareness Initiative, which highlighted a growing emphasis on operationalizing precision nephrology through community-based screening, access to genetic testing, patient education, and longitudinal follow-up for individuals at risk for AMKD. Beyond therapeutics alone, the initiative reflected broader recognition that successful implementation of precision kidney care may require expanded screening infrastructure, multidisciplinary engagement, workforce development, and community-based outreach programs designed to improve earlier identification and access to care.

The Future of Congress Engagement and Scientific Communication

The rapid expansion of therapeutic innovation may also reshape how pharmaceutical companies engage clinicians at major nephrology congresses. SCM26 reflected increasingly experience-oriented and highly interactive engagement strategies throughout the exhibit hall—with sponsorship activities emphasizing networking spaces, educational experiences, wellness areas, and other branded activations designed to foster clinician engagement.

As the nephrology landscape becomes increasingly crowded and mechanism-driven, more interactive, educational, and experience-oriented communication strategies may become important differentiators for conveying scientific value and maintaining clinician attention.

What's Next?

The field appears to be entering a period in which successful kidney disease management will depend not only on therapeutic innovation but also on operational scalability. Earlier diagnosis, expanded access to genetic testing, culturally responsive care, multidisciplinary coordination, and practical integration into nephrology workflows may become increasingly important determinants of real-world adoption and long-term patient impact.

As more targeted therapies enter the market, the nephrology landscape is likely to become increasingly biologically segmented, implementation focused, and centered on preserving long-term kidney health through earlier and more individualized intervention.

Reported by The HWP Group's Tony Chong, PharmD